Upgrade to SI Premium - Free Trial

Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference

March 5, 2018 7:30 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 2:50 p.m. ET. The conference will be held March 12-14, 2018 at The Boston Marriott Copley Place.

A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

Dicerna Pharmaceuticals, Inc.

Investors:

Rx Communications Group

Paula Schwartz, 917-322-2216

[email protected]

or

Media:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

[email protected]

Source: Dicerna Pharmaceuticals, Inc.

Categories

Press Releases